CN104771388B - A kind of pharmaceutical preparation and the application in preparation treatment depression and enteritis medicine thereof - Google Patents
A kind of pharmaceutical preparation and the application in preparation treatment depression and enteritis medicine thereof Download PDFInfo
- Publication number
- CN104771388B CN104771388B CN201510159535.8A CN201510159535A CN104771388B CN 104771388 B CN104771388 B CN 104771388B CN 201510159535 A CN201510159535 A CN 201510159535A CN 104771388 B CN104771388 B CN 104771388B
- Authority
- CN
- China
- Prior art keywords
- depression
- otilonium bromide
- medicine
- treatment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to chemicals technical field, invention entitled a kind of pharmaceutical preparation and the application in preparation treatment depression and enteritis medicine thereof, relate to a kind of otilonium Bromide medicine and the application in preparation treatment depression, post-stroke depression, paralepsy disease, chronic enteritis, irritable bowel syndrome, enterospasm medicine thereof.The otilonium Bromide medicine that the present invention provides is otilonium Bromide tablet, Otilonium bromide capsule, otilonium Bromide enteric coatel tablets, otilonium Bromide enteric coated capsule.The present invention provides the clinical application of technique extension otilonium Bromide, and the most also the treatment for diseases such as depression, post-stroke depression, paralepsy disease, chronic enteritis, irritable bowel syndrome, enterospasm provides new medication selection and clinic diagnosis scheme.
Description
Technical field
The present invention relates to chemicals technical field, particularly to a kind of otilonium Bromide medicine and new pharmaceutical use thereof.
Background technology
Post-stroke depression (post-stroke depression) is one of common complication of apoplexy.Serious sick
People may produce the thought committed suicide, and as taken precautions against not in time, some patients may cause the consequence committed suiside.It is and stroke event
It is correlated with, the affective disorder disease of clinical manifestation depressive mood.
One, depressed sign
At least the cerebral apoplexy patient of 40%～50% has the experience of depression at Post stroke, mostly occurs post-stroke 2 months
～1 year.Owing to the generation of depressive reaction is the most hidden, being difficult to be noticeable, some patient, owing to there is aphasis, makes depression
Shape can not be detected, often until thunder bolt is just known after occurring.If the performance to depressive state has early recognized, note more
The emotion of meaning patient and the mental status, this tragedy can be avoided completely.
Two, Clinical types
1, major depression: depressive symptom: sad, anxiety, early awakening, loss of appetite, world-weary or suicide；
Natural history: 1 year；
Cerebral lesion position: left hemisphere cortex of frontal lobe or Basal ganglia.
2, light-duty depression: depressive symptom: decline, social shrinks back, hebetude, and sleep disorder is shed tears；
Natural history: 1～2 year；
Cerebral lesion position: non-constant.
Three, clinical manifestation
1, emotion and the change of personality: depressed, emotional lability, often feel like grievance and want to cry, language reduces, do not like with
People contacts, suspicious.
2, sleep bad: often insomnia, dream are many, difficulty falling asleep, or easily wake up or early awakening at insomnia-middle, night.
3, indifferent to: to liking the thing done to lose interest in the past, it is unwilling to participate in doings, often stays at home.
4, uncomfortable: be frequently accompanied by stomach discomfort, appetite decline and lose weight, sometimes sense nervous, uncomfortable in chest, breathe hard,
Pain etc. is altered on dizzy headache, the whole body.
5, ability declines: former competent work and housework are not competent, and panesthesia is tired, is disinclined to activity.
6, pessimistic valueless sense: do not entertain hope future, usually feels lonely, desperate, fears, with helpless, often to feel guilty,
Sometimes there is the thought of suicide.
Four, sickness rate
Post stroke occurs that depressive state is common mental maladjustment in a short time, and the sickness rate of post-stroke depression is according to document
Statistics are 20%～60%, and what depression occurred in post-stroke January accounts for 45.4%, the gentliest, modest depression person account for 91.8%.
All ages and classes sickness rate is the most different, and having experiment statistics, poststroke depression sickness rate is 47.24%, Younger group
Sickness rate is 13.33%, and middle age group sickness rate is 43.18%, and old group sickness rate is 55.88%, and old people relatively adolescence is easier to
Poststroke depression occurs.
Five, patient is paid close attention to
1, the support of family: first kinsfolk must give patient and is more concerned about, gives treatment in life, drum
Encourage patient to participate in social activity as far as is humanly possible.Patient the to be paid close attention to mental status after being ill, accomplishes early to find early treatment.
2, the support of society: good social medical insurance can release the trouble and worry of patient, the leader of unit and colleague
Or the care of friend, be conducive to alleviating and eliminating the unhealthy emotion of patient.
3, psychotherapy: doctor's Cure the Primary Disease, helps patient limb functional rehabilitation itself to have the depression of patient
Therapeutical effect very well.How to exchange with patient, understand the mental activity of patient in time, help patient to eliminate unhealthy emotion, establish war
The confidence of victory disease.
4, Drug therapy: what application was more at present is serotonin reuptake inhibitors (SSRI) such as fluoxetine etc., typically
Take 3～6 months or longer time, if the depression of regular treatment most humans.
Otilonium Bromide, it is adaptable to cramps of gastrointestinal tract and dyskinesia (irritable bowel syndrome, gastritis, gastroduodenal
Inflammation, enteritis, esophageal lesion) it can also be used to prepare (esophageal-gastric-duodenoscope, colonoscope, rectoscope before splanchnoscopy
Deng).Otilonium Bromide common formulations is otilonium Bromide tablet, every, otilonium Bromide tablet 40mg Han otilonium Bromide.Oral, every day 2
～3 times, each 1～2.
Inventor chances in clinic diagnosis is put into practice, and Patients with Post Stroke Depression gives otilonium Bromide treatment,
Obtain significant curative effect.After carrying out specification, science, rigorous clinical trial and pharmacodynamic experiment, obtain the technology of the present invention
Scheme.
Summary of the invention
It is an object of the invention to provide a kind of otilonium Bromide medicine.
It is a further object of the present invention to provide otilonium Bromide medicine to treat depression, post-stroke depression in preparation, press down
Application in Yu Fazuo disease, chronic enteritis, irritable bowel syndrome, enterospasm medicine.
It is an object of the invention to be accomplished by:
The application in preparing antidepressant agents of a kind of otilonium Bromide medicine.
Described otilonium Bromide medicine is otilonium Bromide tablet, Otilonium bromide capsule, otilonium Bromide enteric coatel tablets, otilonium Bromide
Enteric coated capsule.
The application in preparation medicament for treatment of depression of the described otilonium Bromide medicine, this medicine can be also used in preparation
Application in treatment post-stroke depression medicine.
The application in preparation medicament for treatment of depression of the described otilonium Bromide medicine, this medicine can be also used in preparation
Application in treatment paralepsy disease drug.
Otilonium Bromide medicine can be also used for the application in preparation treatment chronic enteritis medicine.
Otilonium Bromide medicine can be also used for the application in preparation treatment irritable bowel syndrome medicine.
Otilonium Bromide medicine can be also used for the application in preparation treatment enterospasm medicine.
Detailed description of the invention:
Embodiment 1: the clinical observation on the therapeutic effect of otilonium Bromide treatment post-stroke depression
1 data and method
1.1 clinical data
Select the 52 example Patients with Post Stroke Depressions accepted for medical treatment during in December, 2014 in June, 2014～, the maleest 25 examples,
Female 27 example；Age 51～70 years old, year mean age (58.6 ± 6.1)；The course of disease 4～12 months, average (6.5 ± 2.3) individual month.Institute
Having patient all to check through head CT and MRI and be diagnosed as apoplexy, and meet the depressed diagnostic criteria of CCMD-3, Hamilton is depressed
Scale (HAMD) marks all >=20 points.
Get rid of the person that takes antidepressant drug in the recent period, to otilonium Bromide allergy sufferers, subarachnoid space cerebral hemorrhage, cerebroma etc. other
Nervous system disease person, and mental sickness history person.
Stochastic averagina is divided into observation group and each 26 examples of matched group, and two groups of patients are at physical data ratios such as age, sex, the state of an illness
Relatively no significant difference (P ＞ 0.05), has comparability.
1.2 method
Two groups of patients all give traditional neural internal medicine apoplexy Primary Care.
Matched group does not use any anti depressant medication, is given only psychotherapy；
Observation group gives the treatment of otilonium Bromide sheet on the basis of conventional therapy and psychotherapy, and (Jincheng this pharmacy of sea is limited
Company, traditional Chinese medicines quasi-word H20066490), initial dose 120mg/d, if treatment takes effect after 3 weeks not yet, increase drug dose extremely
240mg/d, continuously treatment 2 months.
1.3 observation index
After continuous treatment 2 months, observe depression evaluation, adverse effect before and after two groups of clinical efficacies of contrast, treatment, and
8～12 months are followed up a case by regular visits to, observed and recorded depression incidence after drug withdrawal.
1.4 efficacy evaluation
(1) according to HAMD depression scale evaluation clinical efficacy:
Score value before deduction rate=(score value after score value treatment before treatment)/treatment
HAMD deduction rate >=75% is recovery from illness, and HAMD deduction rate >=50% is effective, and HAMD deduction rate >=25% is effectively,
HAMD deduction rate ＜ 25% is invalid.
Total effective rate=cure rate+obvious effective rate+effective percentage；
(2) depressive emotion evaluation criteria uses HAMD depression scale and ZungShi self rating depressive scale (SDS) to evaluate.
1.5 statistical analysis
Using SPSS13.0 statistics software to be analyzed, enumeration data employing rate (%) represents, measurement data employing (
± S) represent, compare employing χ between group2Checking with t, P ＜ 0.05 is Variant statistical meaning.
2 results
2.1 liang of group Clinical efficacies
After treating 2 months, observation group's overall clinical efficacy rate is 92.31%, hence it is evident that higher than the 61.54% of matched group, compares between group
Relatively difference has statistical significance, P ＜ 0.05.(referring to table 1)
1 liang of table group Clinical efficacy comparison (n)
Note: compare with matched group, ※ P ＜ 0.05
2.2 liang of group depressive disorders evaluations are observed
Two groups treatment after HAMD and SDS scoring all significantly lower than treatment before, but observation group treatment after HAMD with
SDS, hence it is evident that less than matched group, between group, comparing difference has statistical significance, P ＜ 0.05.(referring to table 2)
2 liang of table group depressive disorders evaluation compare (± S, point)
Note: with this group before treatment, ※ P ＜ 0.05；Compare with after treatment of control group, △ P ＜ 0.05
2.3 untoward reaction
After observation group's application otilonium Bromide treatment, through coherence checks such as routine blood test, electrocardiogram, hepatic and renal functions, it is showed no
Abnormal.
2.4 Follow-up results
After treatment 8～follow up a case by regular visits to for 12 months, observation group's depression is fallen ill 2 examples (7.69%), hence it is evident that less than 13 examples of matched group
(50.00%), between group, comparing difference has statistical significance, P ＜ 0.05.
3 conclusions
This result of study shows, after treating 2 months, observation group's overall clinical efficacy rate is 92.31%, hence it is evident that higher than matched group
61.54%；HAMD and SDS after observation group's treatment, hence it is evident that less than matched group；After treatment 8～follow up a case by regular visits to for 12 months, observation group presses down
Strongly fragrant sickness rate 7.69%, hence it is evident that less than the 50.00% of matched group.Result is pointed out, and gives post-stroke depression in early days difficult to understand for bromine
Ammonium anti depressant therapy, contributes to improving patients ' psychological and the mental status during treatment, treatment retarded depression relapse rate is low, plays anti-pressing down
Strongly fragrant therapeutic purposes, and then may advantageously facilitate neurological rehabilitation, and drug safety.
In sum, otilonium Bromide treatment post-stroke depression determined curative effect, can improve patients ' psychological emotion and spirit
State, and drug safety, have preferably effect to improving function of nervous system.
Embodiment 2: the effect experiment research of otilonium Bromide treatment depression
1 material
1.1 medicine
(1) test medicine (otilonium Bromide sheet): Jincheng Health Pharmaceutical Co., Ltd., traditional Chinese medicines quasi-word H20066490.
(2) positive control drug (fluoxetine tablet): Pharmaceutical Co Ltd, Changzhou Pharmaceutical Factory No.4, traditional Chinese medicines quasi-word H19980139.
1.2 animal
ICR male mice, body weight 18～22 g, Beijing Vital River Experimental Animals Technology Co., Ltd. provide, close
Lattice card SCXK(capital) 2014-0035.All animals are bought for 1 week in advance, conventional raising.
1.3
Instrument Medlab Biological Signal Collecting System (Nanjing Yi Mei Science and Technology Ltd.), JZ100 type 100g tension force changes
Energy device (Gaobeidian City Xin Hang mechanical & electronic equipment corporation, Ltd), (Shanghai Suo Guang electronics is limited for Sony DSC2P8 DV
Department), MC-145 electronic clinical thermometer (Dalian, Omron company limited).
2 methods
2. 1 Tail suspension test
Normal mouse randomized blocks is divided into 3 groups, i.e. blank group, positive drug fluoxetine Hydrochloride group (gives hydrochloric acid fluorine
Western spit of fland 3.5mg kg-1, (given otilonium Bromide 3.5mg kg by reagent otilonium Bromide group-1).Respectively organize all by 0. 2 mL
(10 g)-1Body weight gastric infusion.Every day 1 time, successive administration 7 d, blank group is to deionized water.After last is administered, 1h enters
Row experiment.Use immobilization with adhesive tape on the line of 100 g tonotransducers mice tail end (at tail point 2 cm) so that it is in
Hanging state by the feet, head is connected to Medlab Biological Signal Collecting System from laboratory table about 15cm, transducer, after adapting to 2 min,
Dead time (s) within record 4min.
2. 2 mouse forced swimming test
Animal packet and administering mode, dosage, time, after last is administered, 1h tested with 2. 1.Will
Mice is single puts into high 20 cm, diameter 18 cm, the depth of water 10 cm, in the water vat of water temperature (23 ± 2) DEG C, observes
6 min, adapt to 2 min, the accumulative dead time (s) in 4 min after record.
2. 3 mice Reserpine antagonistic test
The observation normal mouse randomized blocks of temperature decline is divided into 4 groups, i.e. blank group, model group, hydrochloric acid fluorine west
Spit of fland group (3.5mg kg-1), otilonium Bromide group (3.5mg kg-1).Group is all by 0.2 mL (10g)-1Body weight gastric infusion.Often
Day 1 time, successive administration 7d, blank group gavage is to deionized water.1h after last is administered, by 1.6 mg kg-1Dosage abdomen
Chamber injection reserpine, surveys mice anus temperature (being inserted at mice anal about 1.5cm by electronic clinical thermometer probe) after 2h.
2. 4 statistical procedures
Experimental result all use mean ± standard deviation (± s) represent, use the variance in SPSS13. 0 software to divide
Analysis (ANOVA) is tested, and P < 0. 05 represents that difference has significance.
3 results
3. 1 impact on the mouse tail suspension dead time
Test result indicate that, otilonium Bromide group can substantially shorten the mouse tail suspension dead time, shows with blank group comparing difference
Write (P < 0. 05), and be better than positive control drug (fluoxetine Hydrochloride).It is shown in Table 3.
Table 3 on the impact of mouse tail suspension dead time (± s, n=20)
Note: compare * P < 0. 05 with blank group.
3. 2 impact on the mouse forced swimming test dead time
Test result indicate that, otilonium Bromide group can substantially shorten the mouse forced swimming test dead time, poor with blank group
Different notable (P < 0. 05), and it is better than positive control drug (fluoxetine Hydrochloride).It is shown in Table 4.
Table 4 on the impact of mouse forced swimming test dead time (± s, n=20)
Note: compare * P < 0. 05 with blank group.
3. 3 impact on reserpine induced mice temperature decline
Test result indicate that, otilonium Bromide group can significantly resist reserpine induced mice temperature decline, compares with model group
Significant difference (P < 0. 05), and it is better than positive control drug (fluoxetine Hydrochloride).It is shown in Table 5.
Table 5 on the impact of reserpine induced mice temperature decline (± s, n=20)
Note: compare * P < 0. 05 with blank group.
4 conclusions and discussion
The animal model of depression is a lot, and rat force swimming test and Mouse Forced Swim Test have simply, funds are few, quick
The feature that sense is stronger with reliability, therefore this research carries out preliminary study initially with the two model to otilonium Bromide.Experiment
Result shows, otilonium Bromide can significantly shorten the dead time of rat force swimming test and Mouse Forced Swim Test, shows that it has
There is antidepressant effect.
The above is only the preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For Yuan, under the premise without departing from the principles of the invention, it is also possible to make some improvements and modifications, these improvements and modifications also should
It is considered as protection scope of the present invention.
Claims (1)
1. the application treated in post-stroke depression medicine prepared by an otilonium Bromide medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510159535.8A CN104771388B (en) | 2015-04-07 | 2015-04-07 | A kind of pharmaceutical preparation and the application in preparation treatment depression and enteritis medicine thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510159535.8A CN104771388B (en) | 2015-04-07 | 2015-04-07 | A kind of pharmaceutical preparation and the application in preparation treatment depression and enteritis medicine thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104771388A CN104771388A (en) | 2015-07-15 |
| CN104771388B true CN104771388B (en) | 2017-01-04 |
Family
ID=53613378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510159535.8A Expired - Fee Related CN104771388B (en) | 2015-04-07 | 2015-04-07 | A kind of pharmaceutical preparation and the application in preparation treatment depression and enteritis medicine thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104771388B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101053562A (en) * | 2006-04-12 | 2007-10-17 | 北京德众万全药物技术开发有限公司 | Otilonium bromide capsule |
-
2015
- 2015-04-07 CN CN201510159535.8A patent/CN104771388B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN104771388A (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beltrami et al. | Sleep in the intensive care unit | |
| Jones et al. | Pain management for women in labour: an overview of systematic reviews | |
| Gosseries et al. | Amantadine, apomorphine and zolpidem in the treatment of disorders of consciousness | |
| CN107308161A (en) | The purposes of levocetirizine and montelukast in treatment influenza, common cold and inflammation | |
| Xu et al. | Effect of wrist-ankle acupuncture therapy combined with auricular acupuncture on cancer pain: A four-parallel arm randomized controlled trial | |
| Harris | CDC assesses risk from BA. 2.86, highly mutated COVID-19 variant | |
| US20090012039A1 (en) | Use of methylcobalamin nasal spray to treat disorders | |
| Ramteke et al. | Efficacy of Nasya (nasal medication) in coma: A case study | |
| Harris | FDA approves maternal RSV vaccine | |
| CN104771388B (en) | A kind of pharmaceutical preparation and the application in preparation treatment depression and enteritis medicine thereof | |
| CN114028396B (en) | Application of tetrandrine in preparation of medicine for treating fibromyalgia | |
| RU2464976C1 (en) | Method of treating patients in vegetative condition | |
| Harris | Artemisinin Resistance Increasing | |
| CN103721068B (en) | A kind of medicament for the treatment of infantile anorexia | |
| CN106265713B (en) | Purposes of the cordycepin in the drug for preparing depression and its quick anti-depression drug being prepared | |
| Rigo et al. | Guillain Barré syndrome: epidemiological clinical profile and nursing care | |
| CN104623382A (en) | Traditional Chinese medicine for treating insomnia caused by internal disturbance due to phlegm heat | |
| Philpott | Fostering a healthy community: Flu vaccines and advice | |
| CN106491524B (en) | A kind of Betahistine Hydrochloride oral liquid and preparation method thereof and new application | |
| CN106668024A (en) | Western medicine composition for treating neurasthenia and application thereof | |
| Liang et al. | The effect of prophylactic rewarming on postoperative nausea and vomiting among patients undergoing laparoscopic hysterectomy: a prospective randomized clinical study | |
| Harris | One in 5 Males Worldwide Has High-Risk Genital HPV | |
| Harris | Severe COVID-19 Linked to Enduring Immune System Changes | |
| Harris | Deep Brain Stimulation May Improve Function Years After Stroke | |
| Harris | Binge drinking, other substance use up in midlife adults |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Xiuqin Inventor before: Wang Li Inventor before: Ding Liman Inventor before: Liu Ling Inventor before: Wu Pingan |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20161024 Address after: 261041 Shandong city of Weifang province Kuiwei Guangwen street Weifang People's Hospital medical department Applicant after: Wang Xiuqin Address before: 222007 Jiangsu city of Lianyungang Province Lake Road No. 38, Jiangsu Science Park venture in Lianyungang Province Chinese medicine higher occupation technical school medical nursing department Applicant before: Wang Li |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170104 Termination date: 20170407 |